Advertisement

Topics

Glenmark Shapes Immuno-Oncology Play With Early-Stage APC Asset

14:30 EDT 21 Jun 2017 | SCRIP

Glenmark Pharmaceuticals has in-licensed a small molecule oncology compound from APC Therapeutics Inc, expanding its interests in the promising immuno-oncology...

      

Related Stories

 

Original Article: Glenmark Shapes Immuno-Oncology Play With Early-Stage APC Asset

NEXT ARTICLE

More From BioPortfolio on "Glenmark Shapes Immuno-Oncology Play With Early-Stage APC Asset"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...